<!DOCTYPE html>
<html lang="pt-br">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>New Antibiotic Could Be a Breakthrough in Treatment for Killer TB, Trial Suggests | Re:Notícias</title>
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bulma@0.9.4/css/bulma.min.css">
    <style>
        html {
            height: 100%;
        }

        body {
            display: flex;
            flex-direction: column;
            min-height: 100vh;
            margin: 0;
        }

        main {
            flex-grow: 1;
        }
    </style>
    <script defer src="https://use.fontawesome.com/releases/v5.15.4/js/all.js"></script>
</head>
<body>

    <nav class="navbar is-light" role="navigation" aria-label="main navigation">
  <div class="container">
    <div class="navbar-brand">
      <a class="navbar-item" href="https://drakeshin.github.io/renoticia.github.io/">
        <strong class="is-size-4">Re:Notícias</strong>
      </a>

      <a role="button" class="navbar-burger" aria-label="menu" aria-expanded="false" data-target="navbarMenuPrincipal">
        <span aria-hidden="true"></span>
        <span aria-hidden="true"></span>
        <span aria-hidden="true"></span>
      </a>
    </div>

    <div id="navbarMenuPrincipal" class="navbar-menu">
      <div class="navbar-start">
        
          
            <a class="navbar-item" href="/renoticia.github.io/esportes/">
              Esportes
            </a>
          
        
          
            <a class="navbar-item" href="/renoticia.github.io/saude/">
              Saúde
            </a>
          
        
          
            <a class="navbar-item" href="/renoticia.github.io/negocios/">
              Negócios
            </a>
          
        
      </div>
    </div>
  </div>
</nav>

    <main>
        
<section class="section">
  <div class="container">
    <div class="columns is-centered">
      <div class="column is-three-quarters">

        
        <h1 class="title is-2 has-text-centered mb-5">
          New Antibiotic Could Be a Breakthrough in Treatment for Killer TB, Trial Suggests
        </h1>

        
        <div class="level is-mobile mb-4">
          <div class="level-left">
            <div class="level-item">
              <p class="subtitle is-6 has-text-grey">
                <time datetime=" 2025-11-19T20:42:00Z">
                  Publicado em 19/11/2025 às 20:42
                </time>
              </p>
            </div>
          </div>

          
          <div class="level-right">
            <div class="level-item">
              
              <a href="https://science.slashdot.org/story/25/11/19/1820223/new-antibiotic-could-be-a-breakthrough-in-treatment-for-killer-tb-trial-suggests?utm_source=rss1.0mainlinkanon&amp;utm_medium=feed" target="_blank" class="button is-small is-primary is-outlined">
                Ver Fonte Original
              </a>
            </div>
          </div>
          
        </div>

        <hr>

        
        <div class="content is-medium">
          
A new treatment for tuberculosis could boost cure rates and shorten the time needed to treat the disease by months, trial results suggest. The Guardian: Globally, an estimated 10.7 million people fell ill with TB last year and 1.23 million died from it. In its annual report on tuberculosis, launched last week, the World Health Organization said it remained a "major global public-health problem" and the leading infectious cause of death. [...] Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday. 

The trial involved 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania and Uganda, with different dose regimens. All participants had "drug-sensitive" tuberculosis, meaning a standard cocktail of drugs can safely treat them but researchers believe TB infections that are resistant to standard treatment could also be helped. The trial suggested a sorfequiline-based regimen could be used for anyone testing positive, said Dr Maria Beumont, vice-president of TB Alliance.<p><div class="share_submission" style="position:relative;">
<a class="slashpop" href="http://twitter.com/home?status=New+Antibiotic+Could+Be+a+Breakthrough+in+Treatment+for+Killer+TB%2C+Trial+Suggests%3A+https%3A%2F%2Fscience.slashdot.org%2Fstory%2F25%2F11%2F19%2F1820223%2F%3Futm_source%3Dtwitter%26utm_medium%3Dtwitter"><img src="https://a.fsdn.com/sd/twitter_icon_large.png"></a>
<a class="slashpop" href="http://www.facebook.com/sharer.php?u=https%3A%2F%2Fscience.slashdot.org%2Fstory%2F25%2F11%2F19%2F1820223%2Fnew-antibiotic-could-be-a-breakthrough-in-treatment-for-killer-tb-trial-suggests%3Futm_source%3Dslashdot%26utm_medium%3Dfacebook"><img src="https://a.fsdn.com/sd/facebook_icon_large.png"></a>



</div></p><p><a href="https://science.slashdot.org/story/25/11/19/1820223/new-antibiotic-could-be-a-breakthrough-in-treatment-for-killer-tb-trial-suggests?utm_source=rss1.0moreanon&amp;utm_medium=feed">Read more of this story</a> at Slashdot.</p><iframe src="https://slashdot.org/slashdot-it.pl?op=discuss&amp;id=23849459&amp;smallembed=1" style="height: 300px; width: 100%; border: none;"></iframe>
        </div>

        
        
        <div class="mt-6">
          <a href="/renoticia.github.io/recentes/" class="button is-light is-link">
            
            &larr; Voltar para a lista de Recentes
          </a>
        </div>
        

      </div>
    </div>
  </div>
</section>

    </main>

    <footer class="footer">
      <div class="content has-text-centered">
        <p>
          &copy; 2025 Re:Notícias.
        </p>
      </div>
    </footer>

    <script src="https://drakeshin.github.io/renoticia.github.io/js/navbar.js"></script>
</body>
</html>